abstract |
The present invention provides anti-obesitynproteins wherein at least one of the Trp 100 or Trp 138nis replaced by Glu, Asp, His, Lys or Arg, which when administerednto a patient regulate fatntissue. Accordingly, such agents allow patients to overcomentheir obesity handicap and live normal lives with muchnreduced risk for type 2 diabetes, cardiovascular disease,nand cancer. |